BEYFORTUS (nirsevimab-alip)
ANTIVIRAL MONOCLONAL ANTIBODIES · RESPIRATORY SYNCYTIAL VIRUS PNEUMONIA PREVENTION
SANOFI-PASTEUR
Drug class
Antiviral Monoclonal Antibodies
Antiviral monoclonal antibodies are a specialized class of targeted biologic therapeutics engineered to provide passive immunity against specific viral pathogens. Read more about Antiviral Monoclonal Antibodies
2 drugs in this class 2 manufacturers
Drugs in Antiviral Monoclonal Antibodies
ENFLONSIA (clesrovimab-cfor)
ANTIVIRAL MONOCLONAL ANTIBODIES · RESPIRATORY SYNCYTIAL VIRUS PNEUMONIA PREVENTION
Merck Sharp & Dohme
Filter & compare in the drug finder →
Opens the drug finder with Antiviral Monoclonal Antibodies preselected. Add indication or manufacturer filters there.
Antiviral monoclonal antibodies are a specialized class of targeted biologic therapeutics engineered to provide passive immunity against specific viral pathogens.
Their principal mechanism involves binding with high affinity to critical viral surface antigens or host entry receptors, thereby directly neutralizing the virus by blocking viral attachment, fusion, and cellular entry, while also engaging host immune effector functions such as antibody-dependent cellular cytotoxicity to clear infected cells.
Clinically, these agents are utilized for the prophylaxis and treatment of severe viral infections, most notably respiratory syncytial virus, SARS-CoV-2, Ebola virus disease, and HIV-1.
-
nih.gov
Antiviral monoclonal antibodies are a specialized class of targeted biologic therapeutics engineered to provide passive immunity against specific viral pathogens Clinically, these agents are utilized for the prophylaxis and treatment of severe viral infections, most notably respiratory syncytial virus, SARS-CoV-2, Ebola virus disease, and HIV-1
-
nih.gov
Antiviral monoclonal antibodies are a specialized class of targeted biologic therapeutics engineered to provide passive immunity against specific viral pathogens Clinically, these agents are utilized for the prophylaxis and treatment of severe viral infections, most notably respiratory syncytial virus, SARS-CoV-2, Ebola virus disease, and HIV-1
-
nih.gov
Their principal mechanism involves binding with high affinity to critical viral surface antigens or host entry receptors, thereby directly neutralizing the virus by blocking viral attachment, fusion, and cellular entry, while also engaging host immune effector functions such as antibody-dependent cellular cytotoxicity to clear infected cells
-
nih.gov
Their principal mechanism involves binding with high affinity to critical viral surface antigens or host entry receptors, thereby directly neutralizing the virus by blocking viral attachment, fusion, and cellular entry, while also engaging host immune effector functions such as antibody-dependent cellular cytotoxicity to clear infected cells
-
nih.gov
Their principal mechanism involves binding with high affinity to critical viral surface antigens or host entry receptors, thereby directly neutralizing the virus by blocking viral attachment, fusion, and cellular entry, while also engaging host immune effector functions such as antibody-dependent cellular cytotoxicity to clear infected cells
-
nih.gov
Clinically, these agents are utilized for the prophylaxis and treatment of severe viral infections, most notably respiratory syncytial virus, SARS-CoV-2, Ebola virus disease, and HIV-1
Sign in to follow this class
Following a drug class requires a free Physicians Office Resource account.